Sourcing a qualified Bronchogen BALF composition supplier requires verified peptide purity, analytical consistency, and documented low endotoxin levels. Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide studied in preclinical pulmonary models to evaluate changes in bronchoalveolar lavage fluid (BALF) cellular profiles, cytokine concentrations, and tissue remodeling. PX1 Research delivers laboratory-grade Bronchogen backed by ISO 17025 third-party analytical testing.
Sourcing a qualified Bronchogen BALF composition supplier requires verified peptide purity, analytical consistency, and documented low endotoxin levels. Bronchogen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide studied in preclinical pulmonary models to evaluate changes in bronchoalveolar lavage fluid (BALF) cellular profiles, cytokine concentrations, and tissue remodeling. PX1 Research delivers laboratory-grade Bronchogen backed by ISO 17025 third-party analytical testing.
Bronchogen is a synthetic short bioregulatory tetrapeptide with the primary sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Belonging to the class of Khavinson peptide bioregulators, Bronchogen was engineered to mimic endogenous peptide signaling mechanisms within bronchial and alveolar tissue. Preclinical studies suggest that short peptide sequences like Bronchogen can cross nuclear membranes and interact directly with specific histone proteins and DNA promoter regions, modulating gene expression profiles related to cellular differentiation, structural protein synthesis, and local immune responses.
In vitro models utilizing primary airway epithelial cells demonstrate that Bronchogen influences the transcription of genes responsible for maintaining mucociliary clearance and cell-to-cell tight junction integrity. By targeting gene transcription without requiring complex surface receptor cascades, this tetrapeptide serves as a powerful instrument for investigators probing respiratory epigenetics, cellular aging, and tissue homeostasis. Laboratory researchers evaluating pulmonary remodeling utilize the compound to observe structural shifts in bronchial tissue architecture under controlled experimental stress.
Bronchoalveolar lavage fluid (BALF) analysis is a standard analytical protocol in preclinical respiratory physiology used to evaluate cellular immune cell infiltrate, protein exudation, and biochemical markers within the epithelial lining fluid of the lungs. By sampling BALF in animal models of induced acute lung injury, chronic obstructive airway models, or toxin exposures, investigators can quantify total cell counts, differential cell counts (macrophages, neutrophils, lymphocytes, and eosinophils), and soluble inflammatory mediators.
When evaluating how peptide administration alters pulmonary conditions, changes in BALF composition serve as primary quantitative end-points. Preclinical research indicates that exposure to exogenous stressors significantly increases neutrophil recruitment, protein concentration, and pro-inflammatory cytokine expression (such as IL-1β, IL-6, and TNF-α) within the lavage fluid. Research protocols evaluating our bronchogen research peptide assess whether pretreatment or concurrent administration alters these lavagial markers, offering mechanistic insight into mucosal barrier stabilization and local inflammatory cascades.
Published preclinical literature examining Bronchogen in animal models of pulmonary pathology demonstrates significant alterations in key BALF parameters following peptide exposure. In rodent models subjected to toxic inhaled irritants or pro-inflammatory challenge, administration of Bronchogen was associated with a statistically significant reduction in total BALF cellularity, driven primarily by decreased neutrophilic and macrophage infiltration into the alveolar space.
Furthermore, biochemical profiling of BALF supernatant in these studies revealed attenuated levels of lipid peroxidation products, reduced total protein concentration (indicating preserved microvascular barrier function), and a shift toward anti-inflammatory cytokine expression profiles. Investigators utilizing pulmonary biomarker assays rely on these published baseline findings to design comparative studies measuring gene expression, apoptosis markers, and extracellular matrix deposition in chronic respiratory disease models.
In pulmonary and tissue repair research, investigators frequently evaluate multiple short peptide sequences side-by-side to discern sequence-specific bioregulatory effects. While Bronchogen (Ala-Glu-Asp-Leu) specifically targets bronchial tissue gene expression, related short peptides exhibit distinct cellular tropisms. For instance, Chonluten (Trp-Glu-Asp)—another prominent short peptide bioregulator—is extensively studied in respiratory models for its complementary action on mucosal immunity and lung fibroblast proliferation.
Similarly, research projects focused on broader systemic tissue repair and vascular stabilization frequently incorporate BPC-157 alongside localized respiratory peptides. While BPC-157 influences angiogenic pathways and nitric oxide signaling across gastrointestinal and musculoskeletal tissues, Bronchogen demonstrates a targeted regulatory influence on respiratory epithelial transcription. Accessing these compounds through our comprehensive catalog of research peptides allows principal investigators to execute robust, multi-peptide comparative study designs.
Selecting a reliable supplier for laboratory-grade peptides requires stringent evaluation of analytical testing protocols. Synthetic peptides intended for quantitative BALF analysis or sensitive in vitro cellular assays must be free from chemical impurities, residual solvents, TFA (trifluoroacetic acid) toxicity, and bacterial endotoxins. Even trace levels of endotoxins (lipopolysaccharides) can artificially spike inflammatory cell counts and cytokine levels in BALF, completely invalidating experimental control groups.
A qualified supplier must provide comprehensive batch-specific documentation verified by independent laboratories. Essential criteria include high-resolution Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight and sequence identity, and quantitative Limulus Amebocyte Lysate (LAL) testing to guarantee endotoxin limits below 0.01 EU/μg. Establishing these rigorous quality parameters ensures reproducible data across consecutive research cohorts.
To maintain structural stability and prevent peptide degradation, laboratory personnel must adhere to standardized handling protocols. Lyophilized Bronchogen should be stored at -20°C or -80°C in a desiccated environment immediately upon arrival. Lyophilized cakes stored under these conditions remain stable for extended periods, resisting hydrolytic and oxidative degradation.
When preparing solutions for in vitro assays or animal administration models, reconstitution should be performed using sterile, cold, buffer-grade solvents such as Phosphate-Buffered Saline (PBS, pH 7.4) or sterile water for injection. Avoid vigorous vortexing; gently invert or swirl the vial until the lyophilized powder is completely dissolved. Once reconstituted, stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles, which can induce aggregation or peptide cleavage. Aliquoted solutions stored at -80°C remain stable for research procedures over several months.
Every research shipment from PX1 Research includes access to a lot-specific Certificate of Analysis (COA) produced by an independent ISO 17025 accredited laboratory. A valid COA is the foundation of experimental integrity, allowing investigators to verify the exact purity and identity of their research materials before beginning expensive animal trials or cell culture protocols.
When reviewing a PX1 Research COA for Bronchogen, researchers can evaluate the raw RP-HPLC chromatogram showing a single sharp peak corresponding to >98% purity, with clear retention time integration. The accompanying mass spectrum demonstrates a primary mass-to-charge ratio (m/z) matching the theoretical molecular weight of Ala-Glu-Asp-Leu (432.43 g/mol). Furthermore, endotoxin quantification values are explicitly reported, ensuring that lavagial fluid parameter changes observed during experiments result solely from peptide action rather than bacterial contamination.
PX1 Research operates as a premier American supplier of high-purity research peptides, supporting academic institutions, biotechnology firms, and contract research organizations nationwide. All synthetic peptides are produced in cGMP-compliant manufacturing facilities and subjected to rigorous multi-tiered quality control checks. By maintaining fully domestic synthesis and analytical testing pipelines, PX1 Research eliminates the quality control risks associated with unverified overseas distributors.
To support high-throughput screening and longitudinal research projects, PX1 Research maintains state-of-the-art fulfillment centers in California and Arizona. Orders placed Monday through Friday ship same-day, ensuring fast transit times and temperature-controlled integrity. For large-scale studies requiring consistent single-lot batch sizes, laboratories can establish a dedicated wholesale laboratory account to lock in batch consistency and volume supply. Explore our broader peptide research library to review technical whitepapers, analytical standards, and sequence specifications.
What is Bronchogen's chemical sequence and molecular weight?
Bronchogen is a synthetic tetrapeptide with the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). It has a molecular formula of C18H32N4O9 and a molecular weight of approximately 432.43 g/mol.
How does Bronchogen alter BALF composition in preclinical models?
In preclinical pulmonary challenge models, Bronchogen administration has been observed to reduce total immune cell infiltration into bronchoalveolar lavage fluid (BALF), decrease pro-inflammatory cytokine concentrations (IL-1β, IL-6, TNF-α), and lower overall protein leakage from impaired vascular barriers.
Why is endotoxin testing critical when purchasing Bronchogen for BALF studies?
Bacterial endotoxins (LPS) trigger acute inflammatory cell influx and cytokine release within airway tissues. If a research peptide contains trace endotoxins, it can contaminate BALF analytical results, masking or confounding the true biological effects of the compound being tested.
What analytical methods verify the purity of PX1 Research Bronchogen?
PX1 Research verifies Bronchogen purity using lot-specific Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity percentages (>98%), Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight identification, and LAL assays for endotoxin quantification.
How should research-grade Bronchogen be reconstituted in the lab?
Bronchogen should be reconstituted under a sterile laminar flow hood using sterile PBS (pH 7.4) or high-purity water. The vial should be gently swirled until fully dissolved and aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw degradation.
What is the difference between Bronchogen and Chonluten?
Both are bioregulatory short peptides evaluated in respiratory models; however, Bronchogen is a tetrapeptide (Ala-Glu-Asp-Leu) primarily investigated for bronchial epithelial transcription, while Chonluten is a tripeptide (Trp-Glu-Asp) frequently studied for mucosal immune regulation and fibroblast response.
Can PX1 Research supply bulk quantities of Bronchogen for large animal cohorts?
Yes. PX1 Research offers custom batch sizing and bulk procurement options for institutional accounts. Researchers can request custom lot matching to ensure entire multi-animal study protocols utilize a single unified manufacturing lot.
Is Bronchogen supplied by PX1 Research suitable for human clinical use?
No. All products supplied by PX1 Research, including Bronchogen, are strictly for laboratory research, in vitro assays, and preclinical animal investigation. They are not intended for human or veterinary clinical use, administration, or therapy.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.